Larik 75

Pregabalin

Adults w/ central & peripheral neuropathic pain including diabetic peripheral neuropathy & post-herpetic neuralgia. Generalized anxiety disorder. Management of fibromyalgia. Adjunctive therapy for adults w/ partial seizure w/ or w/o secondary generalization.

Recommended dose: 150-600 mg daily given in 2 or 3 divided doses. Neuropathic pain Initially 150 mg daily. May be increased to 300 mg daily after a 3-7 day interval. Max: 600 mg daily after an additional 7-day interval. Epilepsy Initially 150 mg daily. May be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. Generalized anxiety disorder 150-600 mg daily given in 2 or 3 divided doses. Initially 150 mg daily. May be increased to 300 mg daily after 1 wk. Following an additional wk, dose may be increased to 450 mg daily. Max: 600 mg daily after an additional wk. Fibromyalgia Usual dose range: 300-450 mg daily in 2 divided doses. Initially 75 mg bid, may be increased to 150 mg bid w/in 1 wk. Patients who do not experience sufficient benefit May further increase to 225 mg bid. Max: 600 mg daily after an additional wk. Renal impairment CrCl ≥60 mL/min 150 mg bid or tid, 300 mg bid or tid, 450 mg bid or tid, 600 mg bid or tid, 30-60 mL/min 75 mg bid or tid, 150 mg bid or tid, 225 mg bid or tid, 300 mg bid or tid, 15-30 mL/min 25-50 mg once daily or bid, 75 mg once daily or bid, 100-150 mg once daily or bid, 150 mg once daily or bid, <15 mL/min 25 mg once daily, 25-50 mg once daily, 50-75 mg once daily, 75 mg once daily. Supplementary dose following hemodialysis 25 mg as single dose. Max: 100 mg as single dose.

May be taken with or without food.

Hypersensitivity.

Discontinue immediately if symptoms of angioedema eg, facial, perioral, or upperway swelling occur. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. W/drawal symptoms after discontinuation of short- & long-term treatment. May need to adjust hypoglycemic medications in diabetics who gain wt on treatment. Visual blurring & other changes in visual acuity. Severe CHF. Carefully evaluate patients for history of drug abuse or misuse. Improved renal function following discontinuation or dose reduction. May cause dizziness & somnolence influencing the ability to drive or operate machinery. Women of childbearing potential should use effective contraception. Should not be used during pregnancy. Lactation. Childn. Increased occurrence of accidental injury (fall) in the elderly (>65 yr).

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia; abnormal coordination, tremor, dysarthria, amnesia, memory impairment, attention disturbance, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abnormal distention, dry mouth; muscle cramp, arthralgia, back pain, pain in limb, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, feeling drunk, abnormal feeling, fatigue; increased wt.

Additive cognitive & gross motor function impairment w/ oxycodone. Resp failure & coma w/ other CNS depressants. Reduced lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) w/ medications having the potential to produce constipation eg, opioid analgesics.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

D